Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.

Younis HS, Crosby J, Huh JI, Lee HS, Rime S, Monia B, Henry SP.

Blood. 2012 Mar 8;119(10):2401-8. doi: 10.1182/blood-2011-10-387134. Epub 2012 Jan 13.

2.

Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.

Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, Gailani D, MacLeod AR, Tucker EI, Gruber A, Hanson SR, Monia BP.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1670-8. doi: 10.1161/ATVBAHA.113.301282. Epub 2013 Apr 4. Erratum in: Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):e127. Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):e130.

3.

Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.

Zhang H, Löwenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP.

Blood. 2010 Nov 25;116(22):4684-92. doi: 10.1182/blood-2010-04-277798. Epub 2010 Aug 31.

4.

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; FXI-ASO TKA Investigators.

N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.

5.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

Henry SP, Bolte H, Auletta C, Kornbrust DJ.

Toxicology. 1997 Jun 27;120(2):145-55.

PMID:
9184201
6.

Coagulation factor XI as a novel target for antithrombotic treatment.

Löwenberg EC, Meijers JC, Monia BP, Levi M.

J Thromb Haemost. 2010 Nov;8(11):2349-57. doi: 10.1111/j.1538-7836.2010.04031.x. Review.

7.

Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.

Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, Henry SP.

J Pharmacol Exp Ther. 2012 Nov;343(2):489-96. doi: 10.1124/jpet.112.197426. Epub 2012 Aug 22.

8.

Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.

Sheehan JP, Lan HC.

Blood. 1998 Sep 1;92(5):1617-25.

9.

Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.

Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA.

Toxicol Sci. 1998 Dec;46(2):365-75.

PMID:
10048140
10.

Inhibition of coagulation by a phosphorothioate oligonucleotide.

Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10.

PMID:
9361909
11.

Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.

Mavromatidis G, Dinas K, Delkos D, Goutzioulis F, Vosnakis C, Hatzipantelis E, Garipidou V, Rousso D.

Int J Hematol. 2007 Oct;86(3):222-4.

PMID:
17988987
12.

Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.

Webb MS, Tortora N, Cremese M, Kozlowska H, Blaquiere M, Devine DV, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):155-63.

PMID:
11446591
13.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.

Invest New Drugs. 2005 Oct;23(5):467-77.

PMID:
16133798
14.
15.

Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits.

Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, Weitz JI.

Blood. 2014 Mar 27;123(13):2102-7. doi: 10.1182/blood-2013-12-540872. Epub 2014 Feb 5.

16.

[The inherited coagulation factor XI deficiency caused by intronic mutation IVS J-4delgttg].

Xie S, Wang HL, Wang XF, Wu WM, Zhou RF, Wang WB, Hu YQ, Wang ZY.

Zhonghua Xue Ye Xue Za Zhi. 2005 Mar;26(3):144-7. Chinese.

PMID:
15946525
17.

Nonsense mutation in exon V of the factor XI gene does not abolish platelet factor XI expression.

Shirk RA, Konkle BA, Walsh PN.

Br J Haematol. 2000 Oct;111(1):91-5.

PMID:
11091186
18.

Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery.

Yamashita A, Nishihira K, Kitazawa T, Yoshihashi K, Soeda T, Esaki K, Imamura T, Hattori K, Asada Y.

J Thromb Haemost. 2006 Jul;4(7):1496-501.

19.

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.

Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA.

J Pharmacol Exp Ther. 2002 Dec;303(3):1334-43.

20.

A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.

Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, Monia B, Nemunaitis J.

Cancer. 2001 Sep 1;92(5):1265-71.

PMID:
11571742
Items per page

Supplemental Content

Write to the Help Desk